{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:26:50Z","timestamp":1791512810659,"version":"4.3.4"},"reference-count":30,"publisher":"Massachusetts Medical Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Evidence"],"published-print":{"date-parts":[[2022,2,22]]},"DOI":"10.1056\/evidoa2100047","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T21:56:47Z","timestamp":1640210207000},"source":"Crossref","is-referenced-by-count":51,"title":["Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery"],"prefix":"10.1056","volume":"1","author":[{"given":"Deepak L.","family":"Bhatt","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles V.","family":"Pollack","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Mississippi School of Medicine, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Mazer","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"INSERM UMR1148, University of Paris, Paris"},{"name":"H\u00f4pital Bichat, Assistance Publique-H\u00f4pitaux de Paris, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"James","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Ramnath","sequence":"additional","affiliation":[{"name":"PhaseBio Pharmaceuticals, Inc., Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Arnold","sequence":"additional","affiliation":[{"name":"PhaseBio Pharmaceuticals, Inc., Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Mays","sequence":"additional","affiliation":[{"name":"PhaseBio Pharmaceuticals, Inc., Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret R.","family":"Umstead","sequence":"additional","affiliation":[{"name":"PhaseBio Pharmaceuticals, Inc., Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[{"name":"SFJ Pharmaceuticals, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Hickey","sequence":"additional","affiliation":[{"name":"Inference, Inc., Chesterbrook, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Jennings","sequence":"additional","affiliation":[{"name":"MLM Medical Labs, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Curry","sequence":"additional","affiliation":[{"name":"MLM Medical Labs, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Lee","sequence":"additional","affiliation":[{"name":"PhaseBio Pharmaceuticals, Inc., Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.192"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908077"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31887-2"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"e_1_3_5_8_2","unstructured":"Food and Drug Administration. Ticagrelor prescribing information. 2016."},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22357"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.011"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0806848"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622928"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901778"},{"key":"e_1_3_5_14_2","unstructured":"PhaseBio Pharmaceuticals I. PhaseBio receives FDA Breakthrough Therapy designation for PB2452 for the reversal of the antiplatelet activity of ticagrelor. 2019 (https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-receives-fda-breakthrough-therapy-designation-pb2452)."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607887"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.2467"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.029"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.048"},{"key":"e_1_3_5_21_2","unstructured":"Food and Drug Administration. Plavix (clopidogrel bisulfate) package insert. 2017."},{"key":"e_1_3_5_22_2","unstructured":"Food and Drug Administration. Brilinta (ticagrelor) package insert. 2016."},{"key":"e_1_3_5_23_2","unstructured":"Food and Drug Administration. Effient (prasugrel) package insert. 2018."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.141572"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0706859"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.08.009"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814051"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.061"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502000"}],"container-title":["NEJM Evidence"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T21:34:34Z","timestamp":1649712874000},"score":1,"resource":{"primary":{"URL":"https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2100047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,22]]}},"alternative-id":["10.1056\/EVIDoa2100047"],"URL":"https:\/\/doi.org\/10.1056\/evidoa2100047","relation":{},"ISSN":["2766-5526"],"issn-type":[{"value":"2766-5526","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}